144 related articles for article (PubMed ID: 27158141)
21. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition.
Akiu M; Tsuji T; Sogawa Y; Terayama K; Yokoyama M; Tanaka J; Asano D; Sakurai K; Sergienko E; Sessions EH; Gardell SJ; Pinkerton AB; Nakamura T
Bioorg Med Chem Lett; 2021 Jul; 43():128048. PubMed ID: 33887438
[TBL] [Abstract][Full Text] [Related]
23. Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening.
Yamaguchi D; Imaizumi T; Yagi K; Matsumoto Y; Nakashima T; Hirose A; Kashima N; Nosaka Y; Hamada T; Okawa K; Nishiya Y; Kubo K
Sci Rep; 2019 May; 9(1):7742. PubMed ID: 31123329
[TBL] [Abstract][Full Text] [Related]
24. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
25. A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.
Lameijer LN; Ernst D; Hopkins SL; Meijer MS; Askes SHC; Le Dévédec SE; Bonnet S
Angew Chem Int Ed Engl; 2017 Sep; 56(38):11549-11553. PubMed ID: 28666065
[TBL] [Abstract][Full Text] [Related]
26. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
[TBL] [Abstract][Full Text] [Related]
28. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
[TBL] [Abstract][Full Text] [Related]
29. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
30. Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Sadrerafi K; Mason EO; Lee MW
Drug Des Devel Ther; 2018; 12():987-995. PubMed ID: 29731606
[TBL] [Abstract][Full Text] [Related]
31. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW
J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118
[TBL] [Abstract][Full Text] [Related]
32. Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Ozgencil F; Eren G; Ozkan Y; Guntekin-Ergun S; Cetin-Atalay R
Bioorg Med Chem; 2020 Jan; 28(1):115217. PubMed ID: 31818629
[TBL] [Abstract][Full Text] [Related]
33. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
34. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
[TBL] [Abstract][Full Text] [Related]
35. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
Galli U; Travelli C; Massarotti A; Fakhfouri G; Rahimian R; Tron GC; Genazzani AA
J Med Chem; 2013 Aug; 56(16):6279-96. PubMed ID: 23679915
[TBL] [Abstract][Full Text] [Related]
36. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
38. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
Sadrerafi K; Zargham EO; Lee MW
Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512
[TBL] [Abstract][Full Text] [Related]
39. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for resistance to diverse classes of NAMPT inhibitors.
Wang W; Elkins K; Oh A; Ho YC; Wu J; Li H; Xiao Y; Kwong M; Coons M; Brillantes B; Cheng E; Crocker L; Dragovich PS; Sampath D; Zheng X; Bair KW; O'Brien T; Belmont LD
PLoS One; 2014; 9(10):e109366. PubMed ID: 25285661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
